Skip to content

DiGA Cara Care für Reizdarm - Evaluation of a non-invasive, non-additionally burdensome, prospective, multicentered, two-armed, randomized trial with parallel group design

DiGA Cara Care für Reizdarm - Evaluation of a non-invasive, non-additionally burdensome, prospective, multicentered, two-armed, randomized trial with parallel group design

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026631
Enrollment
374
Registered
2021-10-06
Start date
2021-12-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K58.1 K58.2 K58.3 K58.8

Interventions

Group 1: Access to the full version of the App Group 2: Standard of Care and no application of the App Cara Care für Reizdarm or an alternative App

Sponsors

HiDoc Technologies GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Medically confirmed diagnosis according to ICD-10-GM (K58.- i.e.: K58.1, K58.2, K58.3, K58.8). ? signed Informed Consent Form. ? Access to tablet/smartphone with internet access. ? Willingness to use DiGA Cara Care for IBS on a regular, independent basis for at least 12 weeks. ? Willingness to answer questions at four time points over a minimum of 12 weeks.

Exclusion criteria

Exclusion criteria: •Age 70 years •Pregnancy •Addiction or other illness, including mental illness (e.g., dementia, i.e., F00-F07), which may not enable patients to assess the nature and scope as well as possible consequences of participation in the study •Insufficient knowledge of the German language which is necessary to participate in the trial •Past use of DiGA Cara Care for irritable bowel syndrome for a period of more than 2 weeks

Design outcomes

Primary

MeasureTime frame
The alteration of disease severity - measured by Irritable Bowel Syndrome - Severity Scoring System (IBS-SSS) in the intervention and control groups will be used as the primary endpoint. Quality of life (measured using IBS-QOL). Work and activity impairment (measured using WPAI-IBS) Health literacy (measured using HLS-EU-Q16). Data was collected using standardized health questionnaires.

Secondary

MeasureTime frame
Perception of anxiety (measured using GAD-7) Perception of depressiveness (measured using PHQ-9) Data was collected using standardized health questionnaires.

Countries

Germany

Contacts

Public ContactStefan Lüth

Städtisches Klinikum Brandenburg GmbHHochschulklinikum der MHBZentrum für Innere Medizin II

s.lueth@klinikum-brandenburg.de03381411600

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026